申请人:BAYER PHARMA AKTIENGESELLSCHAFT
公开号:US20140249168A1
公开(公告)日:2014-09-04
The present application relates to novel trifluoromethyl-substituted fused pyrimidines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
本申请涉及新颖的三氟甲基取代的融合嘧啶类化合物,以及它们的制备方法,单独或与其他化合物联合用于治疗和/或预防疾病,以及用于生产治疗和/或预防疾病的药物,特别是用于治疗和/或预防心血管疾病。